Literature DB >> 27830286

[TNM-Classification of localized prostate cancer : The clinical T-category does not correspond to the required demands].

J Herden1, A Heidenreich2, L Weißbach3.   

Abstract

BACKGROUND: The TNM staging system for localized prostate cancer (PCa) divides tumors based on clinical parameters into a clinical (c)T category and, after radical prostatectomy (RP), a pathological (p)T category.
OBJECTIVES: This study examines the extent to which the cT and the pT category correspond to each other and whether the two categories differ in their prediction for organ-confined disease. PATIENTS AND METHODS: Data of 687 RP patients were collected in a prospective, noninterventional, multicenter health service research study for the treatment of localized PCa (HAROW). Group comparisons were performed by analysis of variance and student t‑test as well as the chi-squared test or the Fisher exact test.
RESULTS: Clinical cT1 category (62.9%) and pathological pT2c category (56.6%) were diagnosed most frequently. The correspondence of cT and pT category was 15% for cT2a , 10.5% for cT2b, and 55% for cT2c. An extraprostatic extension (≥pT3) was observed for the categories cT1 and cT2 in 23.5% and 36.4% (p < 0.001), differences in the subcategories cT2a-c were not significant: cT2a = 28.8%, cT2b = 42.1%, and cT2c = 38.8% (p = 0.194). Tumors with a pathologically extraprostatic extension were not recognized clinically in >50%.
CONCLUSIONS: For localized PCa there is low agreement between clinical and pathologic T category, thus, often leading to understaging. An adaptation of the T classification of the TNM system with division into "not palpable" and "palpable" appears sufficient for a prognostic prediction.

Entities:  

Keywords:  Digital rectal examination; HAROW-Study; Health service research; Prostate cancer; TNM-staging system

Mesh:

Year:  2016        PMID: 27830286     DOI: 10.1007/s00120-016-0264-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  26 in total

1.  Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?

Authors:  Joe Philip; Subhajit Dutta Roy; Mohammed Ballal; Christopher S Foster; Pradip Javlé
Journal:  BJU Int       Date:  2005-05       Impact factor: 5.588

2.  An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Henrik Møller; Tim Oliver; Victor Reuter; Peter T Scardino; Jack Cuzick; Daniel M Berney
Journal:  Mod Pathol       Date:  2010-09-10       Impact factor: 7.842

Review 3.  Staging prostate cancer.

Authors:  R F Hoedemaeker; A N Vis; T H Van Der Kwast
Journal:  Microsc Res Tech       Date:  2000-12-01       Impact factor: 2.769

4.  Staging of prostate cancer.

Authors:  D G Bostwick; R P Myers; J E Oesterling
Journal:  Semin Surg Oncol       Date:  1994 Jan-Feb

5.  Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging.

Authors:  Herbert Augustin; Markus Graefen; Jüri Palisaar; Jakob Blonski; Andreas Erbersdobler; Fedor Daghofer; Hartwig Huland; Peter G Hammerer
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

6.  The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.

Authors:  C Gosselaar; R Kranse; M J Roobol; S Roemeling; F H Schröder
Journal:  Prostate       Date:  2008-06-15       Impact factor: 4.104

7.  Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.

Authors:  Umberto Capitanio; Vincenzo Scattoni; Massimo Freschi; Alberto Briganti; Andrea Salonia; Andrea Gallina; Renzo Colombo; Pierre I Karakiewicz; Patrizio Rigatti; Francesco Montorsi
Journal:  Eur Urol       Date:  2008-02-26       Impact factor: 20.096

8.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade.

Authors:  B B Cantrell; D P DeKlerk; J C Eggleston; J K Boitnott; P C Walsh
Journal:  J Urol       Date:  1981-04       Impact factor: 7.450

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.